The 12 most recent market catalysts affecting $COLL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 13, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Adjusts Collegium Pharmaceutical Price Target to $41 From $48
Barclays adjusted its price target for Collegium Pharmaceutical, Inc. down to $41 from $48 on November 13, 2026. Despite this reduction, the firm reiterated its 'Overweight' rating…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
Colliers Releases Report on India's Green Office Stock Growth
Colliers released a report forecasting that nearly 70% of Grade A office inventory in India's top seven cities will be green-certified by the end of 2026, driven by corporate ESG g…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 65
Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement
Collegium Pharmaceutical has reached a settlement with Grünenthal, resolving a patent infringement lawsuit related to its Nucynta products. This agreement terminates the existing l…
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 55
Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50
Oppenheimer's initiation of coverage on Collegium Pharmaceutical (COLL) with an Outperform rating and a $50 price target is a positive development for the company. Analyst coverage…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45
Leerink Partners, a notable investment bank, has initiated coverage on Collegium Pharmaceutical (COLL) with an 'Outperform' rating and a $45 price target. This event is significant…
Aug 19, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48
Barclays analyst Glen Santangelo reiterated an 'Overweight' rating for Collegium Pharmaceutical, signaling continued confidence in the company's fundamentals. However, the price ta…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Collegium Pharma shares are trading higher after the company announced a $50 million accelerated share repurchase program.
The $50 million accelerated share repurchase program by Collegium Pharma (COLL) is a strong positive signal to the market. Share repurchases reduce the number of outstanding shares…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Collegium Pharmaceutical Announces $50M Accelerated Share Repurchase Agreement With Jefferies, With Initial Delivery Of 1,556,420 Shares; $100M To Remain Under Program
This accelerated share repurchase (ASR) by Collegium Pharmaceutical is a significant corporate action, indicating management believes the stock is undervalued and aims to enhance s…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
Piper Sandler Reiterates Neutral on Collegium Pharmaceutical, Lowers Price Target to $43
Piper Sandler analyst David Amsellem reiterated a 'Neutral' rating on Collegium Pharmaceutical (COLL) while simultaneously lowering the price target from $45 to $43. This action si…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Collegium Pharmaceutical shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a significant corporate catalyst for Collegium Pharmaceutical. The combination of mixed Q2 results, which likely means some metrics missed expectations, an…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 75
Collegium Pharmaceutical Q2 Adj. EPS $1.92 Beats $1.72 Estimate, Sales $199.878M Miss $201.206M Estimate
The headline indicates a mixed financial performance for Collegium Pharmaceutical. The EPS beat suggests strong operational efficiency or better-than-expected margins, which is gen…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 75
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est
Collegium Pharmaceutical (COLL) has announced a significant reduction in its sales guidance for fiscal year 2026, moving from a range of $865M-$895M down to $825M-$855M. This new g…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.